- Home
- FBRX
as 07-26-2024 4:00pm EST
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | DALLAS |
| Market Cap: | 21.4M | IPO Year: | N/A |
| Target Price: | $3.38 | AVG Volume (30 days): | 14.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.38 - $1.03 | Next Earning Date: | 08-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Forte Biosciences Inc. (FBRX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Wagner Paul A. | FBRX | See Remarks | Dec 18 '23 | Buy | $0.75 | 10,000 | $7,525.00 | 1,823,236 | SEC Form 4 |
| Wagner Paul A. | FBRX | See Remarks | Dec 13 '23 | Buy | $0.70 | 10,520 | $7,351.38 | 1,803,236 | SEC Form 4 |
| Wagner Paul A. | FBRX | See Remarks | Dec 13 '23 | Buy | $0.72 | 10,000 | $7,200.00 | 1,813,236 | SEC Form 4 |
| Wagner Paul A. | FBRX | See Remarks | Dec 11 '23 | Buy | $0.65 | 25,000 | $16,187.50 | 1,787,940 | SEC Form 4 |
| Wagner Paul A. | FBRX | See Remarks | Dec 11 '23 | Buy | $0.65 | 4,776 | $3,088.16 | 1,792,716 | SEC Form 4 |
| Wagner Paul A. | FBRX | See Remarks | Dec 7 '23 | Buy | $0.58 | 36,203 | $21,167.89 | 1,747,940 | SEC Form 4 |
| Wagner Paul A. | FBRX | See Remarks | Dec 7 '23 | Buy | $0.62 | 15,000 | $9,300.00 | 1,762,940 | SEC Form 4 |
Latest Forte Biosciences Inc. News
FBRX Breaking Stock News: Dive into FBRX Ticker-Specific Updates for Smart Investing
Newsfile
2 months ago
Edge Total Intelligence Inc. Updates Status of MCTO
GlobeNewswire
2 months ago
Nokia introduces Network Exposure Platform to expand and simplify network API exposure for service providers
CNW Group
2 months ago
HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA
GlobeNewswire
2 months ago
Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY
GlobeNewswire
2 months ago
The sale of Aspo's subsidiary ESL Shipping's Supramax vessels has been completed on June 11 2024
CNW Group
2 months ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
GlobeNewswire
2 months ago
LED Driver with CAN Bus for Dynamic Automotive Interior RGB Lighting
PR Newswire
2 months ago
IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
Compare FBRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FBRX Forte Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.